Past Papers · SAQ

Anticoagulants — Heparin vs Enoxaparin

Current · V5 (2025) → N4.i Historical · V4 (2023) → Q2.i 5 exam appearances

2025B Q20

Exam question

Describe the following pharmacology of both unfractionated heparin and bivalirudin: (a) indications for use (10% of marks) (b) mechanism of action (30% of marks) (c) monitoring and reversal (10% of marks) (d) important pharmacokinetic differences and considerations when using in the intensive care unit (ICU) (30% of marks) (e) adverse effects (20% of marks).

CICMWrecks answer

Master answer

Canonical sourceCanonical Pharmacopeia comparison
Open in Pharmacopeia
Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field UNFRACTIONATED HEPARIN (UFH)
Haematology · Haematology · Level 1
LOW MOLECULAR WEIGHT HEPARIN (LMWH)
Haematology · Haematology · Level 1
Mechanism of action

Activates antithrombin which then inhibits clotting factors thrombin and factor Xa

Activates antithrombin but due to shorter length preferentially inhibits factor Xa

Absorption

reduced due to endothelial binding (SC), IV

up to 90% via SC (greater than heparin)

Protein binding

very high protein binding.

less prot bind than heparin

Volume of distribution

Vd 0.05-0.1L/kg

Vd ~ 0.1L/kg

Metabolism

By heparinases in the liver,
reticuloendothelial system and kidneys

Hepatic depolymerisation and desulfation to less active fragments

Excretion

urine as inactive metabolites, little change in renal failure

urine as 40% of dose and 10% active fragments, dose adjustment in renal failure

Half-life

variable half life due to protein binding 30 - 150 mins depending on dose

2-4 times longer half-life than heparin
dose independent half time

Adverse Effects Toxicity

Bleeding, Heparin Induced Thrombocytopaenia, Osteoporosis,
Transient transaminitis

Bleeding
Needs adjustment in renal failure
Less HITS and osteoporosis

Class Group

Anticoagulants

Anticoagulants

Indications Uses

1. the prevention of venous thromboembolic disease
2. the priming of haemodialysis and cardiopulmonary bypass machines
and for maintaining the patency of indwelling lines and the treatment of
3. DIC
4. fat embolism, and
5. in the treatment of acute coronary syndromes.

1. the prevention of venous thromboembolic disease
2. the treatment of acute coronary syndromes.

Introduction

Heparin is an anioic, mucopolysaccaride,
organic acid. It occurs naturally in the liver and mast cell granules.

MW: 5000-25000 Daltons

Enoxaparin is a LMWH prepared from
unfractionated heparin by controlled
enzymatic or chemical depolymerisation
Consists of smaller fragments of
Heparin. MW: Average of 5000 Daltons

Legacy Cicm Level

Level 1

Level 1

Presentation

s/c or i.v. - I.U. (not mg) due to variable potencies. 5000IU BD s/c or 5000IU IV then infusion-rate based on wttitrated (APTT)

Usually s/c, but can be given i.v.
20mg or 40mg BD s/c as prophylaxis, 1mg/kg BD s/c as therapeutic dose

Monitor:
Anti-Xa level

Special Points

Reversal:
Protamine by slow infusion (1mg/100i.u.
heparin). Cationic compound forms a stable covalent salt with heparin

Reversal:
Protamine by slow infusion
Less e¬ffective than heparin due to the preferential Xa action (1mg/1mg
LMWH), but max effect is < 60%

Past papers

Exam appearances

5 appearances
Exam Exact exam wording Candidate success
2025B Q20 Describe the following pharmacology of both unfractionated heparin and bivalirudin: (a) indications for use (10% of marks) (b) mechanism of action (30% of marks) (c) monitoring and reversal (10% of marks) (d) important pharmacokinetic differences and considerations when using in the intensive care unit (ICU) (30% of marks) (e) adverse effects (20% of marks). 35%
2024A Q20 Outline the important similarities and differences between unfractionated heparin and enoxaparin using the following headings (20% of marks each): (i) Mechanism of action (ii) Pharmacokinetics (iii) Adverse effects (iv) Dosing (v) Monitoring and reversal 27%
2018B Q20 Describe the pharmacology of heparin highlighting important differences between unfractionated and fractionated (low molecular weight) heparin. 71%
2017B Q05 Compare and contrast unfractionated heparin with low molecular weight heparin 68%
2009B Q20 Compare and contrast the pharmacology of heparin and enoxaparin. 89%